Zanolimumab

DB17376InvestigationalProtein Based Therapies

Zanolimumab is a fully human monoclonal antibody directed against CD4.

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD4
Curator reviewed
Also known as: Humax-cd4 · IMMUNOGLOBULIN, ANTI-(HUMAN CD4 ANTIGEN) (HUMAN MONOCLONAL 6G5 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL 6G5 LIGHT CHAIN, DIMER
Code names: MDX-016

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Zanolimumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.